UroGen Pharma (URGN) Accumulated Expenses (2016 - 2026)

UroGen Pharma (URGN) has reported Accumulated Expenses for 11 consecutive years, with $9.8 million the latest figure, recorded in Q1 2026.

• Quarterly Accumulated Expenses rose 41.19% year-over-year to $9.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.8 million (up 41.19% YoY) and the FY2025 annual result came in at $13.5 million, up 27.87% from the prior year.
• Accumulated Expenses fell to $9.8 million in Q1 2026 per URGN's latest filing, from $13.5 million in the prior quarter.
• Over the last five years, Accumulated Expenses for URGN reached as high as $13.5 million in Q4 2025 and fell as low as $4.9 million in Q1 2023.
• A 5-year average of $8.3 million and a median of $8.2 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses retreated 5.09% — and 2025, when it surged 70.04%.
• Year by year, Accumulated Expenses stood at $8.3 million in 2022, then jumped by 30.97% to $10.8 million in 2023, then dropped by 2.26% to $10.6 million in 2024, then advanced by 27.87% to $13.5 million in 2025, then declined by 27.22% to $9.8 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $9.8 million, $13.5 million, and $11.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.